

Guangxi Sun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8961643/publications.pdf>

Version: 2024-02-01

48
papers

579
citations

623734

14
h-index

677142

22
g-index

52
all docs

52
docs citations

52
times ranked

897
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrated Molecular Characterization of Fumarate Hydratase-deficient Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 1734-1743.	7.0	54
2	Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma. <i>BMC Cancer</i> , 2019, 19, 360.	2.6	52
3	Therapeutic Potential of Human Adipose-Derived Stem Cell Exosomes in Stress Urinary Incontinence – An in Vitro and in Vivo Study. <i>Cellular Physiology and Biochemistry</i> , 2018, 48, 1710-1722.	1.6	46
4	Integrated exome and RNA sequencing of TFE3-translocation renal cell carcinoma. <i>Nature Communications</i> , 2021, 12, 5262.	12.8	40
5	The efficacy and safety of radical prostatectomy and radiotherapy in high-risk prostate cancer: a systematic review and meta-analysis. <i>World Journal of Surgical Oncology</i> , 2020, 18, 42.	1.9	32
6	The prognostic implication of intraductal carcinoma of the prostate in metastatic castration-resistant prostate cancer and its potential predictive value in those treated with docetaxel or abiraterone as first-line therapy. <i>Oncotarget</i> , 2017, 8, 55374-55383.	1.8	30
7	Improved Long-Term Clinical Outcomes And Safety Profile Of Sunitinib Dosing Schedule With 4/2 Switched To 2/1 In Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Cancer</i> , 2018, 9, 3303-3310.	2.5	28
8	AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy. <i>Prostate</i> , 2019, 79, 1553-1562.	2.3	22
9	Differential expression of TIM-3 between primary and metastatic sites in renal cell carcinoma. <i>BMC Cancer</i> , 2019, 19, 49.	2.6	21
10	Pelvic lymph node dissection and its extent on survival benefit in prostate cancer patients with a risk of lymph node invasion >5%: a propensity score matching analysis from SEER database. <i>Scientific Reports</i> , 2019, 9, 17985.	3.3	19
11	The Prognostic Value of the Proportion and Architectural Patterns of Intraductal Carcinoma of the Prostate in Patients with De Novo Metastatic Prostate Cancer. <i>Journal of Urology</i> , 2019, 201, 759-768.	0.4	19
12	Comparison of Current Systemic Combination Therapies for Metastatic Hormone-Sensitive Prostate Cancer and Selection of Candidates for Optimal Treatment: A Systematic Review and Bayesian Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 519388.	2.8	18
13	Circulating tumour DNA reveals genetic traits of patients with intraductal carcinoma of the prostate. <i>BJU International</i> , 2022, 129, 345-355.	2.5	18
14	The impact of multifocal perineural invasion on biochemical recurrence and timing of adjuvant androgen deprivation therapy in high-risk prostate cancer following radical prostatectomy. <i>Prostate</i> , 2017, 77, 1279-1287.	2.3	16
15	Novel nomograms for castration-resistant prostate cancer and survival outcome in patients with de novo bone metastatic prostate cancer. <i>BJU International</i> , 2018, 122, 994-1002.	2.5	16
16	The Adiponectin-AdipoR1 Axis Mediates Tumor Progression and Tyrosine Kinase Inhibitor Resistance in Metastatic Renal Cell Carcinoma. <i>Neoplasia</i> , 2019, 21, 921-931.	5.3	16
17	Dynamic multidisciplinary team discussions can improve the prognosis of metastatic castration-resistant prostate cancer patients. <i>Prostate</i> , 2021, 81, 721-727.	2.3	15
18	Prognostic analysis of postoperative clinically nonmetastatic renal cell carcinoma. <i>Cancer Medicine</i> , 2020, 9, 959-970.	2.8	14

#	ARTICLE	IF	CITATIONS
19	The AKR1C3/AR ϵ 7 complex maintains CRPC tumour growth by repressing B4GALT1 expression. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 12032-12043.	3.6	13
20	What kind of patients with castration-naïve prostate cancer can benefit from upfront docetaxel and abiraterone: A systematic review and a network meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 505-517.	1.6	11
21	Comparison of the prognosis of primary and progressive muscle-invasive bladder cancer after radical cystectomy: A systematic review and meta-analysis. <i>International Journal of Surgery</i> , 2018, 52, 214-220.	2.7	9
22	The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancer. <i>Prostate</i> , 2021, 81, 1191-1201.	2.3	9
23	Comparison of Systemic Treatments for Metastatic Castration-Resistant Prostate Cancer After Docetaxel Failure: A Systematic Review and Network Meta-analysis. <i>Frontiers in Pharmacology</i> , 2021, 12, 789319.	3.5	9
24	Exosomal TUBB3 mRNA expression of metastatic castration-resistant prostate cancer patients: Association with patient outcome under abiraterone. <i>Cancer Medicine</i> , 2021, 10, 6282-6290.	2.8	8
25	Does ductal adenocarcinoma of the prostate (DA) have any prognostic impact on patients with de novo metastatic prostate cancer?. <i>Prostate</i> , 2019, 79, 1673-1682.	2.3	7
26	The prognosis benefits of adjuvant versus salvage radiotherapy for patients after radical prostatectomy with adverse pathological features: a systematic review and meta-analysis. <i>Radiation Oncology</i> , 2019, 14, 197.	2.7	4
27	Survival Outcomes of Radical Prostatectomy + Extended Pelvic Lymph Node Dissection and Radiotherapy in Prostate Cancer Patients With a Risk of Lymph Node Invasion Over 5%: A Population-Based Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 607576.	2.8	4
28	Is Additional Systematic Biopsy Necessary in All Initial Prostate Biopsy Patients With Abnormal MRI?. <i>Frontiers in Oncology</i> , 2021, 11, 643051.	2.8	4
29	Efficacy and Safety of Individualized Schedule of Sunitinib by Drug Monitoring in Patients with Metastatic Renal Cell Carcinoma. <i>Cancer Management and Research</i> , 2021, Volume 13, 6833-6845.	1.9	4
30	Assessment for prognostic value of differentially expressed genes in immune microenvironment of clear cell renal cell carcinoma. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 5416-5432.	0.0	4
31	The effect of additional chemotherapy on high-risk prostate cancer: a systematic review and meta-analysis. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 9061-9070.	2.0	3
32	<p>The validation of the 2014 International Society of Urological Pathology (ISUP) grading system for patients with high-risk prostate cancer: a single-center retrospective study</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 6521-6529.	1.9	3
33	MicroRNA-106a suppresses prostate cancer proliferation, migration and invasion by targeting tumor-derived IL-8. <i>Translational Cancer Research</i> , 2020, 9, 3507-3517.	1.0	3
34	The Impact of Renal Impairment on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitors. <i>Cancer Control</i> , 2020, 27, 107327482097714.	1.8	2
35	The influence of dynamic changes in lipid metabolism on survival outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1454-1463.	1.3	2
36	Adiponectin-AdipoR1 axis in renal cell carcinoma plays a pivotal role in tumor progression and drug resistance.. <i>Journal of Clinical Oncology</i> , 2019, 37, 634-634.	1.6	1

#	ARTICLE	IF	CITATIONS
37	The effect of AKR1C3 on the switch from prednisone to dexamethasone in metastatic castration-resistant prostate cancer patients receiving abiraterone.. Journal of Clinical Oncology, 2020, 38, 133-133.	1.6	1
38	The prognostic role of IDC-P in mCRPC and its predictive value in those treated with docetaxel or abiraterone as first-line therapy.. Journal of Clinical Oncology, 2017, 35, e603-e603.	1.6	1
39	Is it the time to shift paradigms in castration naïve prostate cancer (CNPC): A meta-analysis of upfront docetaxel and abiraterone in men with CNPC.. Journal of Clinical Oncology, 2018, 36, 360-360.	1.6	1
40	The impact of multifocal perineural invasion on biochemical recurrence and timing of adjuvant androgen-deprivation therapy in high-risk prostate cancer following radical prostatectomy.. Journal of Clinical Oncology, 2017, 35, e595-e595.	1.6	0
41	Will second-line nonsteroidal antiandrogen drugs (NSAA) after the failure of bicalutamide affect the therapeutic efficacy of the sequential abiraterone treatment?. Journal of Clinical Oncology, 2018, 36, 337-337.	1.6	0
42	Novel nomograms for castration-resistant prostate cancer and survival outcome in patients with de novo bone-metastatic prostate cancer.. Journal of Clinical Oncology, 2018, 36, 336-336.	1.6	0
43	High-exosomal AKR1C3 mRNA expression as a marker of poor efficacy of abiraterone in metastatic PCa patients.. Journal of Clinical Oncology, 2020, 38, 196-196.	1.6	0
44	Exosomal TUBB3 mRNA expression level to predict prognosis for abiraterone treatment in metastatic prostate patients.. Journal of Clinical Oncology, 2020, 38, 244-244.	1.6	0
45	The efficacy and safety of radical prostatectomy and radiotherapy in high-risk prostate cancer: A systematic review and meta-analysis.. Journal of Clinical Oncology, 2020, 38, 369-369.	1.6	0
46	Genomic landscape and immune microenvironment features of FH-deficient renal cell carcinoma.. Journal of Clinical Oncology, 2020, 38, 717-717.	1.6	0
47	Distinctive landscape of genetic mutation in patients with intraductal carcinoma of the prostate (IDC-P).. Journal of Clinical Oncology, 2020, 38, 192-192.	1.6	0
48	Efficacy of second-line ICIs combined with TKIs among patients with metastatic renal cell carcinoma: a real-world study. Immunotherapy, 2022, 14, 309-320.	2.0	0